Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with 68 Ga-N188.
Jianhua ZhangXiaojiang DuanXueqi ChenZhuochen ZhangHongwei SunJiayin ShouGuangyu ZhaoJianxin WangYongsu MaYinmo YangXiaodong TianQi ShenWei YuZhisong HeYan FanXing YangPublished in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2024)
Nectin cell adhesion molecule 4 (nectin-4) is a transmembrane protein overexpressed on a variety of cancers and plays an important role in oncogenic and metastatic processes. The nectin-4-targeted antibody-drug conjugate enfortumab vedotin has been approved for treating locally advanced or metastatic urothelial cancer, but the efficacy in other types of cancer remains to be explored. The aim of this study was to evaluate the feasibility of nectin-4-targeted PET imaging with 68 Ga-N188 as a noninvasive method to quantify membranous nectin-4 expression in multiple tumor types-an approach that may provide insight for patient stratification and treatment selection. Methods: Sixty-two patients with 16 types of cancer underwent head-to-head 68 Ga-N188 and 18 F-FDG PET/CT imaging for initial staging or detection of recurrence and metastases. Correlation between lesion SUV max and nectin-4 expression determined by immunohistochemistry staining was analyzed in 36 of 62 patients. Results: The SUV max of 68 Ga-N188 had a positive correlation with membranous nectin-4 expression in the various tumor types tested ( r = 0.458; P = 0.005), whereas no association was observed between the SUV max and cytoplasmic nectin-4 expression. The detection rates for patient-based analysis of 68 Ga-N188 and 18 F-FDG PET/CT examinations were comparable (95.00% [57/60] vs. 93.33% [56/60]). In patients with pancreatic cancer, 68 Ga-N188 exhibited a potential advantage for detecting residual or locally recurrent tumors; this advantage may assist in clinical decision-making. Conclusion: The correlation between nectin-4-targeted 68 Ga-N188 PET imaging and membranous nectin-4 expression indicates the potential of 68 Ga-N188 as an effective tool for selecting patients who may benefit from enfortumab vedotin treatment. The PET imaging results provided evidence to explore nectin-4-targeted therapy in a variety of tumors. 68 Ga-N188 may improve the restaging of pancreatic cancer but requires further evaluation in a powered, prospective setting.
Keyphrases
- pet ct
- pet imaging
- poor prognosis
- positron emission tomography
- squamous cell carcinoma
- binding protein
- papillary thyroid
- small cell lung cancer
- cancer therapy
- decision making
- lymph node
- transcription factor
- newly diagnosed
- case report
- photodynamic therapy
- prognostic factors
- rectal cancer
- cell adhesion
- childhood cancer
- neoadjuvant chemotherapy
- radiation therapy
- lymph node metastasis
- drug delivery
- small molecule
- mass spectrometry
- fluorescence imaging
- free survival
- double blind